ESALY - 3 Things In Biotech August 18: Finally A New First-Line Treatment For Liver Cancer
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Eisai and Merck's liver cancer partnership pays off
Company: Eisai (OTCPK:ESALY) and Merck (MRK)
Therapy: Lenvatinib
Disease: Hepatocellular carcinoma (the most common form of liver cancer)
News: The FDA has approved the use of the multitargeted kinase inhibitor lenvatinib for first-line treatment in patients with advanced hepatocellular carcinoma. This makes it just the second kinase inhibitor option in the first-line